Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $1.35 in the prior trading day, Standard BioTools Inc (NASDAQ: LAB) closed at $1.41, up 4.44%. In other words, the price has increased by $4.44 from its previous closing price. On the day, 0.76 million shares were traded. LAB stock price reached its highest trading level at $1.42 during the session, while it also had its lowest trading level at $1.35.
Ratios:
Our goal is to gain a better understanding of LAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 09 ’25 when Casdin Partners Master Fund, L bought 100,000 shares for $1.29 per share. The transaction valued at 128,920 led to the insider holds 60,875,000 shares of the business.
Casdin Partners Master Fund, L bought 250,000 shares of LAB for $319,350 on Sep 04 ’25. The Director now owns 60,775,000 shares after completing the transaction at $1.28 per share. On Sep 03 ’25, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 250,000 shares for $1.27 each. As a result, the insider paid 316,400 and bolstered with 60,525,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 538613056 and an Enterprise Value of 191276320. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 3.49 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 1.11 whereas that against EBITDA is -1.57.
Stock Price History:
The Beta on a monthly basis for LAB is 1.31, which has changed by -0.29850745 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.32, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of. The Stock is 8.07%, while the 200-Day Moving Average is calculated to be 5.17%.
Shares Statistics:
. The Stock has traded on average 1.81M shares per day over the past 3-months and 1139310 shares per day over the last 10 days, according to various share statistics. A total of 381.69M shares are outstanding, with a floating share count of 365.52M. Insiders hold about 4.31% of the company’s shares, while institutions hold 74.20% stake in the company. Shares short for LAB as of 1756425600 were 12169060 with a Short Ratio of 6.72, compared to 1753920000 on 12009245. Therefore, it implies a Short% of Shares Outstanding of 12169060 and a Short% of Float of 4.99.
Earnings Estimates
The dynamic stock of Standard BioTools Inc (LAB) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.09 and -$0.09 for the fiscal current year, implying an average EPS of -$0.09. EPS for the following year is -$0.04, with 1.0 analysts recommending between -$0.04 and -$0.04.
Revenue Estimates
3 analysts predict $18M in revenue for the current quarter. It ranges from a high estimate of $18.3M to a low estimate of $17.7M. As of the current estimate, Standard BioTools Inc’s year-ago sales were $44.97MFor the next quarter, 3 analysts are estimating revenue of $19.3M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $18.4M.
A total of 3 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $100.4M, while the lowest revenue estimate was $78M, resulting in an average revenue estimate of $86.37M. In the same quarter a year ago, actual revenue was $174.43MBased on 3 analysts’ estimates, the company’s revenue will be $79.73M in the next fiscal year. The high estimate is $81M and the low estimate is $78.7M.
